| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
Based on the analysis result of RUNX3 knockout mouse as well as clinical samples of gastric cancer, the following was developed aiming at the functional analysis of RUNX3, and gene diagnosis and the application to carcinogenic prevention and medical treatment. We have already identified several kinds of markers of a gastric cancer precursor cell, and are looking for a stomach cancer precursor cell in the background membrane of an early frequent occurrence stomach cancer excision specimen. Moreover, clinical application of novel HDAC inhibitor FK228, SAHA, etc. has being carried out. We are examining a carcinogenic inhibiting effect with a mouse chemical carcinogenesis model, and considered that it can applied for the cancer prevention using RUNX3 as the molecular target. Furthermore, RUNX3 has played the role important for TGFbeta dependence apoptosis, and participating in the susceptibility of a radiation chemistry treatment became clear (Oncogene, Sakakura et al., 2007). Moreover, we are checking generating of a large intestine pathological change by crossing of RUNX3 knockout mouse and an APC knockout mouse. The molecule (TCF4) which the carcinogenic signal transfer system (Wnt signal system) of colorectal cancer and a RUNX3-TGFbeta signal transfer system overlap is also identified (Cancer Cell, Ito et al, 2009), and the further development can expect from now on. With Luminex system, we establish the quick serological-diagnosis system which can measure quantitatively methylation of two or more genes in many samples in a short time, and are trying for clinical application.
|
